AU2005262701B2 - Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia - Google Patents
Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia Download PDFInfo
- Publication number
- AU2005262701B2 AU2005262701B2 AU2005262701A AU2005262701A AU2005262701B2 AU 2005262701 B2 AU2005262701 B2 AU 2005262701B2 AU 2005262701 A AU2005262701 A AU 2005262701A AU 2005262701 A AU2005262701 A AU 2005262701A AU 2005262701 B2 AU2005262701 B2 AU 2005262701B2
- Authority
- AU
- Australia
- Prior art keywords
- reaction chamber
- gram negative
- breath condensate
- exhaled breath
- lipopolysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002158 endotoxin Substances 0.000 title claims abstract description 162
- 229920006008 lipopolysaccharide Polymers 0.000 title claims abstract description 122
- 201000001178 Bacterial Pneumonia Diseases 0.000 title abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 55
- 238000006243 chemical reaction Methods 0.000 claims description 134
- 208000027096 gram-negative bacterial infections Diseases 0.000 claims description 34
- 241000894006 Bacteria Species 0.000 claims description 33
- 230000008859 change Effects 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 25
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 20
- 239000011159 matrix material Substances 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 238000012544 monitoring process Methods 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 description 29
- 206010035664 Pneumonia Diseases 0.000 description 25
- 238000003556 assay Methods 0.000 description 21
- 102000029749 Microtubule Human genes 0.000 description 20
- 108091022875 Microtubule Proteins 0.000 description 20
- 210000004688 microtubule Anatomy 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000011521 glass Substances 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 239000003570 air Substances 0.000 description 13
- 239000003593 chromogenic compound Substances 0.000 description 13
- 230000000994 depressogenic effect Effects 0.000 description 13
- 230000003115 biocidal effect Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000002826 coolant Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 229920002554 vinyl polymer Polymers 0.000 description 11
- 238000006703 hydration reaction Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000036571 hydration Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 238000011050 LAL assay Methods 0.000 description 7
- 239000003708 ampul Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- -1 disaccharide diphosphate Chemical class 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108090000056 Complement factor B Proteins 0.000 description 6
- 102000003712 Complement factor B Human genes 0.000 description 6
- 241000239218 Limulus Species 0.000 description 6
- 208000032376 Lung infection Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 108010055222 clotting enzyme Proteins 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Chemical class 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 description 3
- 108010040201 Polymyxins Proteins 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000011203 antimicrobial therapy Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 108010072542 endotoxin binding proteins Proteins 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108010048121 pro-clotting enzyme Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007893 endotoxin activity Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000144985 peep Species 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- RLOWDGUBFHHFMQ-IRXDYDNUSA-N (2S)-5-(diaminomethylideneamino)-2-[[2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]acetyl]amino]pentanoic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)O RLOWDGUBFHHFMQ-IRXDYDNUSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 241000239220 Limulus polyphemus Species 0.000 description 1
- 102100035131 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Chemical class 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000405070 Percophidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- CNVGTZZIUPDIEV-PMACEKPBSA-N butyl N-[(2S)-1-[[2-[[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound [N+](=O)([O-])C1=CC=C(NC([C@@H](NC(CNC([C@@H](NC(=O)OCCCC)CC(C)C)=O)=O)CCCNC(N)=N)=O)C=C1 CNVGTZZIUPDIEV-PMACEKPBSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 108010045487 coagulogen Proteins 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000003366 endpoint assay Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Chemical class 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000009420 retrofitting Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/097—Devices for facilitating collection of breath or for directing breath into or through measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012201119A AU2012201119A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201117A AU2012201117A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201120A AU2012201120A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201118A AU2012201118A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57764104P | 2004-06-07 | 2004-06-07 | |
| US60/577,641 | 2004-06-07 | ||
| PCT/US2005/018232 WO2006007180A2 (en) | 2004-06-07 | 2005-05-24 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012201119A Division AU2012201119A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201118A Division AU2012201118A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201117A Division AU2012201117A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| AU2012201120A Division AU2012201120A1 (en) | 2004-06-07 | 2012-02-27 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005262701A1 AU2005262701A1 (en) | 2006-01-19 |
| AU2005262701B2 true AU2005262701B2 (en) | 2011-12-01 |
Family
ID=35784291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005262701A Ceased AU2005262701B2 (en) | 2004-06-07 | 2005-05-24 | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1761166A4 (enExample) |
| JP (2) | JP4804464B2 (enExample) |
| AU (1) | AU2005262701B2 (enExample) |
| BR (1) | BRPI0511846A (enExample) |
| CA (1) | CA2566804A1 (enExample) |
| IL (5) | IL179137A (enExample) |
| MX (1) | MXPA06014248A (enExample) |
| WO (1) | WO2006007180A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7547285B2 (en) | 2003-02-14 | 2009-06-16 | The Charlotte-Mecklenburg Hospital Authority | Device and method for collection of exhaled alveolar breath condensate |
| US7828741B2 (en) | 2002-12-20 | 2010-11-09 | The Charlotte-Mecklenburg Hospital Authority | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia |
| EP1571985B1 (en) | 2002-12-20 | 2009-04-01 | The Charlotte-Mecklenburg Hospital Authority | Disposable hand-held device for collection of exhaled breath condensate |
| KR20100084528A (ko) * | 2007-10-02 | 2010-07-26 | 안나-카린 올린 | 호기 입자의 수집 및 측정 |
| RU2010146772A (ru) * | 2008-06-04 | 2012-07-20 | КейСиАй Лайсензинг, Инк. (US) | Обнаружение инфекции при терапии ран пониженным давлением |
| GB201312635D0 (en) * | 2013-07-15 | 2013-08-28 | Univ Plymouth | Water testing |
| US10413216B2 (en) * | 2016-02-03 | 2019-09-17 | Quintron Instrument Company, Inc. | Breath testing apparatus |
| CN106018362B (zh) * | 2016-05-16 | 2018-06-08 | 江苏国恒检测有限公司 | 一种检测苦味酸的测定器 |
| CN108871908B9 (zh) * | 2018-09-06 | 2024-07-26 | 杭州优思达生物技术股份有限公司 | 生物样本处理装置 |
| EP4013302A1 (en) * | 2019-08-13 | 2022-06-22 | Respiration Scan Ltd | System and method for determining onset and disease progression |
| CN114449957B (zh) * | 2019-08-26 | 2023-11-24 | 泽特奥科技公司 | 利用呼出气诊断结核病和其他疾病 |
| WO2023038582A2 (en) * | 2021-09-10 | 2023-03-16 | National University Of Singapore | Exhaled breath condensate collection kit |
| EP4404848A1 (en) * | 2021-09-20 | 2024-07-31 | Vosbio, Inc. | Devices, methods and kits for biological sample capture and processing |
| AU2024283662A1 (en) * | 2023-06-05 | 2025-12-04 | Charles River Laboratories, Inc. | Recombinant amebocyte clotting factors and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4349626A (en) * | 1980-10-28 | 1982-09-14 | The Monell Chemical Senses Center | Method of detecting Pseudomonas aeruginosa infections utilizing selected ketone and/or sulfur metabolites |
| US5541057A (en) * | 1989-09-18 | 1996-07-30 | Biostar, Inc. | Methods for detection of an analyte |
| US20040234971A1 (en) * | 2001-02-01 | 2004-11-25 | Joany Jackman | Diagnosis of pathogen infections using mass spectral analysis of immune system modulators in post-exposure biological samples |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL59383A (en) * | 1980-02-14 | 1983-03-31 | Technion Res & Dev Foundation | Micromethod for the determination of endotoxins with limulus amebocyte lysate |
| SE9704329D0 (sv) * | 1997-11-25 | 1997-11-25 | Siemens Elema Ab | Gasmätare |
| EP1139870A4 (en) * | 1998-12-18 | 2004-07-28 | Univ Virginia | DEVICE AND METHOD FOR MONITORING ASTHMA |
| EP1169640B1 (en) * | 1999-03-09 | 2005-06-15 | Osmetech PLC | Method for detecting conditions by analysis of aqueous condensate from respiratory gases |
| AU2001261091A1 (en) * | 2000-05-01 | 2001-11-12 | Respiratory Research, Inc. | Method and device for collecting and analyzing exhaled breath |
-
2005
- 2005-05-24 AU AU2005262701A patent/AU2005262701B2/en not_active Ceased
- 2005-05-24 BR BRPI0511846-8A patent/BRPI0511846A/pt not_active IP Right Cessation
- 2005-05-24 WO PCT/US2005/018232 patent/WO2006007180A2/en not_active Ceased
- 2005-05-24 EP EP05753778A patent/EP1761166A4/en not_active Withdrawn
- 2005-05-24 CA CA002566804A patent/CA2566804A1/en not_active Abandoned
- 2005-05-24 MX MXPA06014248A patent/MXPA06014248A/es active IP Right Grant
- 2005-05-24 JP JP2007527565A patent/JP4804464B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-09 IL IL179137A patent/IL179137A/en not_active IP Right Cessation
-
2009
- 2009-05-15 JP JP2009118170A patent/JP4852121B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-19 IL IL218191A patent/IL218191A0/en unknown
- 2012-02-19 IL IL218189A patent/IL218189A0/en unknown
- 2012-02-19 IL IL218188A patent/IL218188A0/en unknown
- 2012-02-19 IL IL218190A patent/IL218190A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4349626A (en) * | 1980-10-28 | 1982-09-14 | The Monell Chemical Senses Center | Method of detecting Pseudomonas aeruginosa infections utilizing selected ketone and/or sulfur metabolites |
| US5541057A (en) * | 1989-09-18 | 1996-07-30 | Biostar, Inc. | Methods for detection of an analyte |
| US20040234971A1 (en) * | 2001-02-01 | 2004-11-25 | Joany Jackman | Diagnosis of pathogen infections using mass spectral analysis of immune system modulators in post-exposure biological samples |
Also Published As
| Publication number | Publication date |
|---|---|
| IL179137A (en) | 2012-07-31 |
| BRPI0511846A (pt) | 2008-01-15 |
| WO2006007180A3 (en) | 2006-11-30 |
| IL218188A0 (en) | 2012-04-30 |
| MXPA06014248A (es) | 2007-06-25 |
| IL218191A0 (en) | 2012-04-30 |
| WO2006007180A2 (en) | 2006-01-19 |
| EP1761166A2 (en) | 2007-03-14 |
| IL179137A0 (en) | 2007-03-08 |
| CA2566804A1 (en) | 2006-01-19 |
| JP2009186487A (ja) | 2009-08-20 |
| AU2005262701A1 (en) | 2006-01-19 |
| JP4852121B2 (ja) | 2012-01-11 |
| IL218190A0 (en) | 2012-04-30 |
| IL218189A0 (en) | 2012-04-30 |
| EP1761166A4 (en) | 2009-11-11 |
| JP4804464B2 (ja) | 2011-11-02 |
| JP2008501976A (ja) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7828741B2 (en) | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia | |
| JP4852121B2 (ja) | 呼気凝縮液中のリポ多糖体を利用するグラム陰性菌性肺炎の診断 | |
| Torres et al. | Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia | |
| Garay et al. | A new test showing abnormal net Na+ and K+ fluxes in erythrocytes of essential hypertensive patients | |
| US20090305331A1 (en) | Kits and methods for determining colon cleanliness | |
| US20130190639A1 (en) | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia | |
| Pomrantz et al. | Comparison of serologic evaluation via agar gel immunodiffusion and fungal culture of tissue for diagnosis of nasal aspergillosis in dogs | |
| Rodrguez de Castro et al. | Quantitative cultures of protected brush specimens and bronchoalveolar lavage in ventilated patients without suspected pneumonia. | |
| Tobin | Diagnosis of pneumonia: techniques and problems | |
| AU2012201120A1 (en) | Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia | |
| Arora et al. | Non-bronchoscopic bronchoalveolar lavage in the microbiological diagnosis of pneumonia in mechanically ventilated patients | |
| Berthold et al. | Use of the lactose-[13C] ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test | |
| Ku et al. | Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis | |
| Grattan-Smith et al. | Viral supraglottitis | |
| Brearley et al. | Endotoxin levels in portal and systemic blood | |
| JP4711846B2 (ja) | 甚急性乳房炎の判定方法 | |
| RU2305838C1 (ru) | Способ прогнозирования возникновения повторных респираторных заболеваний у детей раннего возраста, часто и длительно болеющих орз | |
| Dennesen et al. | The development of ventilator-associated pneumonia does not change aspects of mechanical ventilation | |
| Stewart et al. | The problems diagnosing ventilator-associated pneumonia | |
| Ahsan et al. | Frequency and outcome of ventilator associated pneumonia in an intensive care unit of a tertiary care hospital in Dhaka | |
| Forsah et al. | Bilateral empyema with beta hemolytic group C streptococcus and Streptococcus constellatus co-infection resulting from an esophageal perforation and associated with septic shock, diffuse ST elevation, and new-onset atrial fibrillation | |
| Carvalho et al. | Unusual case of a giant lung abscess initially misdiagnosed and treated as an empyema | |
| RU2324191C2 (ru) | Способ диагностики дисбактериоза кишечника | |
| Abdullaev et al. | ETIOLOGICAL, DIAGNOSTIC AND MORPHOLOGICAL FEATURES OF SEVERE PNEUMONIA (LITERATURE REVIEW) | |
| Solijon o‘g‘li | TESTING FOR TRACHEAL INFECTIONS IN CHILDREN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |